Drug Development

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

Industry groups offered perspectives on the strengths and weaknesses of the European Falsified Medicines Directive.

Implications for APIs in the European Falsified Medicines Directive

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

External manufacturing plays a crucial role in pharmaceutical companies’ supply strategy. The author examines market trends for the captive and merchant global market for active pharmaceutical ingredients and intermediates.

A Shifting Landscape for the Global API Market

Novel, atom-efficient routes to amides from esters and carboxylic acids for more sustainable manufacturing.

Reducing the Complexity of Commercial-Scale Amide Formation

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

New routes enable the efficient synthesis of enantiopure sulfinamides and structurally and sterically diverse P-chiral phosphine oxides.

New Chiral Sulfur and Phosphorous Chemistry from Boehringer Ingelheim

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.

Gauging Investment in High-Potency Manufacturing

The US and EU move forward with measures to fortify the pharmaceutical supply chain.

Strengthening the Supply Chain for Pharmaceutical Ingredients

Cocrystals can enable the formulation of solid dosage drugs, but the FDA's final guidelines have left concerns about how their use could impact development timelines, the drug product manufacturing process, and the intellectual property position of products containing cocrystals.

Cocrystals Can Improve API Properties, But Will the Recent FDA Guidance Slow Adoption of This Technology?

Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.

Elucidating Heterocyclic Chemistry in Pharmaceuticals

A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.

Small-Molecule Drug Development: Recent Study Suggests Limited Binding Sites

Microwave spectroscopy overcomes some of the limitations of circular dichroism and vibrational circular dichroism in analyzing enantiomers.